Skip to main content
Journal cover image

Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines.

Publication ,  Journal Article
Cho, EI; Tan, C; Koski, GK; Cohen, PA; Shu, S; Lee, WT
Published in: Head Neck
June 2010

BACKGROUND: The aim of the present study was to evaluate the therapeutic efficacy of dendritic cell (DC)-tumor fusion hybrids with Toll-like receptor (TLR) agonists. METHODS: DC-tumor fusion hybrids were generated by electrofusion and injected into the inguinal lymph nodes of C57BL/6 mice with 3-day established pulmonary metastases. Paired TLR agonists polyinosine:polycytadilic acid [poly(I:C)] and cytosine-phosphate-guanine (CpG) were then injected intraperitoneally. Enzyme-linked immunosorbent assay (ELISA) was used to evaluate interleukin (IL)-12 production from the DC-tumor fusion hybrids in vitro. RESULTS: Fusion + TLR agonists (60 metastases) had significantly fewer metastases than did the untreated control (262 metastases, p = .0001) and fusion alone (150 metastases, p = .02). ELISA showed that the DC-tumor fusion hybrids yielded 90 pg of IL-12 after TLR stimulation compared with 1610 pg from dendritic cells alone. CONCLUSIONS: CpG and poly(I:C) administered as a third signal with fusion hybrids as described significantly reduce melanoma metastasis compared with fusion hybrids alone. Fusion hybrids do not appear to be a significant source for IL-12 secretion.

Duke Scholars

Published In

Head Neck

DOI

EISSN

1097-0347

Publication Date

June 2010

Volume

32

Issue

6

Start / End Page

700 / 707

Location

United States

Related Subject Headings

  • Vaccines, Synthetic
  • Toll-Like Receptors
  • Specific Pathogen-Free Organisms
  • Recombinant Fusion Proteins
  • Otorhinolaryngology
  • Mice, Inbred C57BL
  • Mice
  • Melanoma, Experimental
  • Lung Neoplasms
  • Interleukin-12
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cho, E. I., Tan, C., Koski, G. K., Cohen, P. A., Shu, S., & Lee, W. T. (2010). Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. Head Neck, 32(6), 700–707. https://doi.org/10.1002/hed.21241
Cho, Edward I., Chunrui Tan, Gary K. Koski, Peter A. Cohen, Suyu Shu, and Walter T. Lee. “Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines.Head Neck 32, no. 6 (June 2010): 700–707. https://doi.org/10.1002/hed.21241.
Cho EI, Tan C, Koski GK, Cohen PA, Shu S, Lee WT. Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. Head Neck. 2010 Jun;32(6):700–7.
Cho, Edward I., et al. “Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines.Head Neck, vol. 32, no. 6, June 2010, pp. 700–07. Pubmed, doi:10.1002/hed.21241.
Cho EI, Tan C, Koski GK, Cohen PA, Shu S, Lee WT. Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. Head Neck. 2010 Jun;32(6):700–707.
Journal cover image

Published In

Head Neck

DOI

EISSN

1097-0347

Publication Date

June 2010

Volume

32

Issue

6

Start / End Page

700 / 707

Location

United States

Related Subject Headings

  • Vaccines, Synthetic
  • Toll-Like Receptors
  • Specific Pathogen-Free Organisms
  • Recombinant Fusion Proteins
  • Otorhinolaryngology
  • Mice, Inbred C57BL
  • Mice
  • Melanoma, Experimental
  • Lung Neoplasms
  • Interleukin-12